Furthermore, Wistar rats with metabolic syndrome treated with dapagliflozin for 2 weeks showed an improvement in cardiomyocyte function through affecting Zn+2-transporters ZIP7, ZIP14, ZIP8 and ZnT7, thus benefiting total oxidative status [108]. Here, SLC39A14 is linked to metabolic syndrome.